Would you continue immune checkpoint inhibitor therapy in a metastatic NSCLC patient with CNS failure if the systemic disease is otherwise controlled?

Great question with limited data to give a "correct answer." I have seen CNS response to checkpoint inhibitors, but I do not expect CNS response from it. In my practice, if I saw truly isolated CNS failure with good systemic control, I would continue checkpoint inhbibitory therapy as long as it was otherwise tolerated and indicated. This is my current practice regardless of line of therapy, rather subject to change as hard data on the subject emerges.